Fig. 4

Interaction between SGLT2 inhibitors and antidiabetic/antihypertensive drugs on eGFR after 3 months of SGLT2 inhibitor therapy. SGLT2i; SGLT2 inhibitors, RASi; renin-angiotensin system inhibitors, CCB; Ca²⁺ channel blockers, DPP4i; DPP4 inhibitors